Literature DB >> 16928616

Urinary podocyte mRNA excretion in children with D+HUS: a potential marker of long-term outcome.

Laura De Petris1, Jilma Patrick, Erica Christen, Howard Trachtman.   

Abstract

BACKGROUND: Diarrhea-associated hemolytic uremic syndrome (D+HUS) causes acute renal failure and may lead to podocyte loss. Objective. To determine if the urinary mRNA excretion of podocyte proteins is detectable in children with D+HUS and if it is a biomarker of a poor long-term outcome.
METHODS: Patients were randomly selected from participants in the SYNSORB Pk trial. Urine samples were collected daily during the first week of hospitalization. Specimens were also obtained in healthy volunteers. Synaptopodin and nephrin mRNA levels were measured using real-time PCR.
RESULTS: Fifteen children, aged 4.9+/-2.8 years, were studied. Patients were categorized based on urinary mRNA levels into normal (marker:GAPDH<or=mean + SD) or high (marker:GAPDH>mean + SD) in controls. Twelve patients (80%) had increased urinary podocyte mRNA excretion; 11 (73%) had high synaptopodin and 5 (33%) had high nephrin mRNA levels. Follow-up data were available in 13/15 patients, all of whom had normal blood pressure, urinalysis, and serum creatinine concentration.
CONCLUSION: The isolation of podocyte mRNA from routine urine samples is feasible in children with D+HUS. Most patients have podocyturia based on synaptopodin and nephrin mRNA excretion. Larger studies with extended follow-up are required to determine the relationship of these biomarkers to long-term renal prognosis in D+HUS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16928616     DOI: 10.1080/08860220600778902

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  8 in total

Review 1.  Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.

Authors:  Carlamaria Zoja; Simona Buelli; Marina Morigi
Journal:  Pediatr Nephrol       Date:  2017-12-06       Impact factor: 3.714

2.  Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.

Authors:  Monica Locatelli; Simona Buelli; Anna Pezzotta; Daniela Corna; Luca Perico; Susanna Tomasoni; Daniela Rottoli; Paola Rizzo; Debora Conti; Joshua M Thurman; Giuseppe Remuzzi; Carlamaria Zoja; Marina Morigi
Journal:  J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 10.121

3.  Shiga toxin 2 targets the murine renal collecting duct epithelium.

Authors:  Mitchell A Psotka; Fumiko Obata; Glynis L Kolling; Lisa K Gross; Moin A Saleem; Simon C Satchell; Peter W Mathieson; Tom G Obrig
Journal:  Infect Immun       Date:  2009-01-05       Impact factor: 3.441

4.  ELISA analysis of urinary nephrin and podocalyxin standardized by aquaporin-2 in adult patients with nephrotic syndrome.

Authors:  Bin Zhu; Xian-fa Li; Xiao-ling Zhu; Yi Lin; Sen Zhong; Cai-feng Zhu; Xuan-li Tang; Yun-qing Hu; Xiao-xia Cheng; Yong-jun Wang
Journal:  J Nephrol       Date:  2014-04-16       Impact factor: 3.902

5.  Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.

Authors:  Tom G Obrig
Journal:  Toxins (Basel)       Date:  2010-12-02       Impact factor: 4.546

Review 6.  Human Urine as a Noninvasive Source of Kidney Cells.

Authors:  Fanny Oliveira Arcolino; Agnès Tort Piella; Elli Papadimitriou; Benedetta Bussolati; Daniel J Antonie; Patricia Murray; Lamberthus van den Heuvel; Elena Levtchenko
Journal:  Stem Cells Int       Date:  2015-05-18       Impact factor: 5.443

7.  Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome.

Authors:  Aamer Imdad; Samuel P Mackoff; David M Urciuoli; Tamkeenat Syed; Emily E Tanner-Smith; Dongmei Huang; Oscar G Gomez-Duarte
Journal:  Cochrane Database Syst Rev       Date:  2021-07-05

Review 8.  Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.

Authors:  Lindsay S Keir; Stephen D Marks; Jon Jin Kim
Journal:  Drug Des Devel Ther       Date:  2012-07-19       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.